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To determine if hepatitis C virus seropositivity and 
active hepatitis B virus infection in HIV-positive patients vary 
with patients’ geographic origins, we studied co-infections 
in HIV-seropositive adults. Active hepatitis B infection was 
more prevalent in persons from Africa, and hepatitis C 
seropositivity was more common in persons from eastern 
Europe. 
Since the introduction of highly active antiretroviral treatment (HAART), non-AIDS defi ning conditions 
have become major causes of illness and death in HIV-in-
fected patients. In particular, liver disease has emerged as 
a major cause of death in the HAART era (1,2). In HIV-in-
fected patients, chronic liver conditions are mostly caused 
by hepatitis C virus (HCV) and hepatitis B virus (HBV) 
(3,4).
Worldwide distribution of both viruses is heterogeneous 
because of different patterns of transmission (5,6). In 
addition, HBV immunization programs at birth were 
implemented in some countries during the 1990s, which has 
led to a decrease in the proportion of chronic HBV carriers 
(6). As a consequence of these different patterns of risk 
and immunization, HCV and HBV prevalence vary across 
countries and even across regions in the same country (7,8). 
Several studies have addressed HBV and HCV prevalence 
in migrants and ethnic minorities (9,10), but few studied 
viral hepatitis co-infections in HIV-infected persons 
according to the patients’ geographic origins (11,12).
In Spain, as in other high-income countries, migrants 
from developing countries represent a growing proportion 
of persons with HIV-infections (13). The question we 
addressed in our study was whether HCV seropositivity 
and active HBV infection in HIV-positive patients vary 
with the patients’ geographic origins.
The Study  
To assess this question, we defi ned active HBV 
infection as the presence in serum of hepatitis B surface 
antigen (HBsAg) and defi ned HCV seropositivity as 
the presence of HCV antibodies. Then we described the 
prevalence of HCV seropositivity and active HBV infection 
in HIV-positive patients from the Cohort of the Spanish 
AIDS Research Network (CoRIS) who had never received 
HAART, according to their geographic origin. In addition, 
we explored the association between HCV seropositivity 
and active HBV infection with geographic origin, taking 
into account potential confounders.
CoRIS is an open, prospective cohort, which integrates 
data from 31 centers from 13 of the 17 autonomous 
communities in Spain. CoRIS inclusion criteria for patients 
are the following: >13 years of age, new to the center, and 
previously untreated with HAART. A detailed description 
of this cohort has been previously reported (14). Patients 
signed informed consent and the study was approved by 
the ethics committees at each participant hospital. For the 
purpose of this study, we collected data from all 4,419 
HIV-positive HAART-naive patients included in CoRIS 
from January 1, 2004, through November 30, 2008.
Serologic tests for HBV and HCV were done by the 
clinical laboratories associated with each of the participating 
sites by using commercially available ELISAs to detect 
HBsAg. HCV antibody testing was performed with a 
commercial ELISA, and positive results were confi rmed by 
immunoblot. For the HBV analyses, we considered only 
those patients who had positive HBsAg results at study 
entry (n = 3,824). Similarly, for the HCV analyses, we only 
considered patients with positive HCV antibody test results 
at entry (n = 3,867).
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CoRIS collected the following variables at cohort 
entry: gender (male or female), age (<31, 31–40, or >40 
years), transmission category (injection drug users [IDU], 
men who have sex with men [MSM], heterosexual contact, 
and other/unknown), educational level (no studies, primary 
school, secondary school, university, and unknown), 
geographic origin (Spain, non-Spanish western Europe, 
eastern Europe and Russia, sub-Saharan Africa, North 
Africa, Latin America, and other/unknown origin), 
serologic markers (positive, negative, and unknown).
Description of baseline characteristics was done by 
frequency distributions. A χ2 test was used to compare 
proportions between geographic origins. We calculated 
univariate odds ratios of association of co-infection with 
sex, transmission category, age at entry into cohort, 
educational level, and geographic origin. Trend score tests 
were used with age and educational level. Multivariate 
logistic regression analysis was used to estimate the 
association of geographic origin with HCV and active 
HBV co-infections. Taking into account previous studies 
(7–11), we decided to include the following variables in the 
multivariate analyses: gender, transmission category, age at 
entry to cohort, and educational level. We used likelihood 
ratio tests to address the adequacy of the model.
Differences at baseline according to geographic origin 
are shown in Table 1. In all studied populations, prevalence 
of HCV seropositivity was 21.8% (95% confi dence interval 
[CI] 20.5%–23.1%). Compared with Spaniards, for whom 
prevalence was 26.5%, HCV seropositivity was higher in 
migrants from eastern Europe, 45.9% (p<0.01), and lower 
in persons from sub-Saharan Africa, North Africa, and 
Latin America, for whom numbers were 10.1% (p<0.01), 
16.4% (p = 0.09), and 4.9% (p<0.01), respectively. No 
signifi cant differences were observed when seropositivity 
was compared with that of persons from Western Europe, 
22.3% (p = 0.30).
In all studied populations, active HBV infection was 
5.8% (95% CI 5.1%–6.6%); when compared to prevalence 
of infections in persons born in Spain (4.9%), active HBV 
infection was more common in persons from western 
Europe, sub-Saharan Africa, and North Africa with 
11.2% (p<0.01), 11.1% (p<0.01), and 10.9% (p<0.05), 
respectively. No signifi cant differences were observed 
between prevalence in Spain and prevalence in persons 
from eastern Europe and Russia, 8.4% (p = 0.15) and Latin 
America, 5.6% (p = 0.46).
Marked differences in HCV seropositivity and active 
HBV infection prevalence according to transmission 
category were also observed, showing higher prevalence 
of co-infection in IDU (HCV 89.5%; HBV 7.8%) than in 
heterosexual persons (HCV 13.0%, p<0.01; HBV 5.1%, 
p<0.05) or MSM (HCV 3.5%, p<0.01; HBV 5.8%, p = 
0.09). Active HBV infection was more common in MSM 
(8.2%) than in heterosexual persons (2.8%, p<0.01) only in 
HIV-positive patients from Latin America.
In analyses adjusted for age group (<31, 31–40, or >40 
years), gender, transmission category (heterosexual, IDU, 
MSM, other) and level of education (no studies, primary 
school, secondary school, university, unknown), geographic 
origin remains a strong risk factor for HCV seropositivity 
(Table 2). Geographic origin in eastern Europe and Russia 
was signifi cantly associated with higher prevalence of HCV 
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Table 1. Sociodemographic characteristics of patients in Cohort of the Spanish Aids Research Network by geographic origin, Spain,
2004–2008*
Patient
characteristic
No. (%) patients 
All Spain  
Western
Europe 
Eastern
Europe 
Sub-Saharan 
Africa North Africa Latin America Other/UNK 
Total 4,419 3,023 136 90 315 67 740 48
Female sex 1,003 (22.70) 574 (18.99) 15 (11.03)† 41 (45.56)‡ 182 (57.78)‡ 24 (35.82)‡ 166 (22.43)† 1 (2.08) 
Age, y 
 <31 1,344 (30.42) 751 (24.84) 23 (16.91) 56 (62.22)‡ 147 (46.67)‡ 18 (26.87) 330 (44.59)‡ 19 (39.58) 
 31–40 1,750 (39.61) 1,197 (39.60) 76 (55.88)‡ 23 (25.56) 105 (33.33) 32 (47.76) 301 (40.68) 16 (33.33) 
 >40 1,325 (29.98) 1,075 (35.56) 37 (27.21) 11 (12.22) 63 (20.00)† 17 (25.37) 109 (14.73)‡ 13 (27.08) 
Transmission
 Heterosexual 1,666 (37.70) 960 (31.76) 30 (22.06) 48 (53.33)‡ 284 (90.16)‡ 50 (74.63)‡ 282 (38.11)† 12 (25.00) 
 IDU 721 (16.32) 641 (21.20) 25 (18.38) 24 (26.67) 5 (1.59) 6 (8.96) 14 (1.89) 6 (12.50) 
 MSM 1,852 (41.91) 1,301 (43.04) 78 (57.35)† 12 (13.33)† 2 (0.63) 6 (8.96) 427 (57.70)‡ 26 (54.17) 
 Other/UNK 180 (4.07) 121(4.00) 3 (2.21) 6 (6.67) 24 (7.62) 5(7.46) 17 (2.30) 4 (8.33) 
Level of studies 
 No studies 303 (6.86) 152 (5.03) 5 (3.68) 9 (10.00) 78 (24.76)‡ 15 (22.39)‡ 41 (5.54) 3 (6.25) 
 Primary  1,416 (32.04) 998 (33.01) 30 (22.06) 33 (36.67) 92 (29.21) 19 (28.36) 236 (31.89) 8 (16.67) 
 Secondary  1,203 (27.22) 839 (27.75) 42 (30.88) 28 (31.11) 39 (12.38)† 14 (20.90) 231 (31.22) 10 (20.83) 
 University 642 (14.53) 459 (15.18) 39 (28.68)† 7 (7.78) 10 (3.17) 7 (10.45) 113 (15.27) 7 (14.58) 
 Unknown 855 (19.35) 575 (19.02) 20 (14.71) 13 (14.44) 96 (30.48)† 12 (17.91) 119 (16.08) 20 (41.67)†
*IDU, injection drug user; MSM, men who have sex with men; UNK, unknown.  
†p<0.05, Ȥ2 test for the difference between proportions of persons from each place of origin and persons born in Spain.   
‡p<0.01. 
seropositivity than was origin in Spain, and sub-Saharan 
African, North African, and Latin American origins were 
associated with lower prevalence of HCV seropositivity. 
Nonetheless, IDU transmission category was the factor that 
showed the greatest association with HCV seropositivity. 
Analyses of association of geographic origin to active HBV 
infection, with data adjusted for age, gender, transmission 
category, and level of education (Table 2), showed that 
origin in Western Europe, sub-Saharan Africa, and North 
Africa was associated with a signifi cantly higher prevalence 
of active HBV infection than origin in Spain.
CoRIS annually undertakes both internal and external 
quality audits. The cohort represents the HIV-positive 
population that initiates care at hospitals in Spain, i.e., 
those whose conditions have been newly diagnosed and, 
therefore, they have not begun HAART at the time of entry 
at cohort. Geographic origin and transmission categories 
are collected as reported by the patient, which could 
produce some misclassifi cation. However, our results are 
consistent, and the association of both co-infections with 
geographic origin is unlikely to be biased. We could not 
hypothesize about risks at origin since data on exposure in 
country of origin (e.g., vaccination, occupation, health care 
received) are not collected in our database.
Conclusions
Geographic origin of HIV-positive patients infl uences 
the epidemiology of both HCV seropositivity and active 
HBV infection in HIV-positive patients who begin HIV 
clinical care in Spain. Although injection drug use remains 
the main risk factor for HCV seropositivity as reported 
by other studies (15), differences by geographic origin 
are maintained in multivariate analyses. For active HBV 
infection, geographic origin is the major risk factor shown 
by HIV-positive patients who seek clinical care for HIV in 
Spain. Our fi ndings suggest that the background prevalence 
of HCV and HBV co-infections in different migrant 
communities does play a role in shaping the epidemiology 
of both co-infections in HIV-positive patients.
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Table 2. Frequencies of hepatitis C virus seropositivity and/or active hepatitis B virus-HIV coinfection in HIV-infected patients and 
multivariate odds ratio of association to sociodemographic variables, Spain, 2004–2008* 
Variable
HCV seropositivity HBsAg seropositivity 
No. (%) patients  Adjusted OR (95% CI) No. (%) patients Adjusted OR (95% CI) 
Sex
 M 3,012 (21.18) NA 2,952 (6.47) 1.00
 F 855 (24.09) 872 (3.67) 0.44 (0.28–0.68) 
Age, y 
 <31 1,168 (9.76) 1.00 1,119 (5.36) NA
 31–40 1,532 (24.22) 2.60 (1.84–3.67) 1,515 (5.54) 
 >40 1,166 (30.79) 3.85 (2.72–5.46) 1,189 (6.64) 
Transmission category 
 Heterosexual 1,400 (13) 1.00 1,467 (5.11) 1.00
 Injection drug use 639 (89.51) 50.67 (36.85–69.68) 618 (7.77) 1.71 (1.11–2.63) 
 Men who have sex with men 1,670 (3.53) 0.33 (0.24–0.45) 1,584 (5.81) 1.33 (0.89–1.98) 
 Other/unknown 158 (19.62) 1.50 (0.97–2.33) 155 (5.16) 0.97 (0.45–2.09) 
Level of studies 
 No studies 272 (32.72) 1.00 262 (8.78) 1.00
 Primary school 1,286 (31.18) 0.80 (0.52–1.24) 1,244 (6.75) 0.82 (0.5–1.36) 
 Secondary school 1,108 (13.09) 0.51 (0.32–0.82) 1,054 (4.27) 0.48 (0.27–0.84) 
 University 591 (5.75) 0.42 (0.24–0.76) 560 (5.54) 0.61 (0.33–1.12) 
 Unknown 610 (28.69) 1.05 (0.66–1.67) 704 (5.68) 0.64 (0.37–1.11) 
Geographic origin 
 Spain 2,650 (26.53) 1.00 2,628 (4.91) 1.00
 Western Europe 121 (22.31) 1.01 (0.51–2.03) 116 (11.21) 2.38 (1.29–4.39) 
 Eastern Europe 85 (45.88) 3.76 (2.06–6.83) 83 (8.43) 2.15 (0.96–4.84) 
 Sub-Saharan Africa 268 (10.07) 0.60 (0.38–0.96) 280 (11.07) 3.63 (2.22–5.92) 
 North Africa 55 (16.36) 0.51 (0.2–1.34) 55 (10.91) 2.96 (1.21–7.23) 
 Latin America 648 (4.94) 0.45 (0.29–0.69) 622 (5.63) 1.30 (0.87–1.93) 
 Other/unknown 40 (17.5) 0.81 (0.26–2.5) 40 (5.00) 0.98 (0.23–4.15) 
*Variables included in the multivariate analyses: gender, transmission category, age at entry into cohort, and educational level. HCV, hepatitis C virus; 
HBsAg, hepatitis B virus surface antigen; OR, odds ratio; CI, confidence interval; NA, not associated in the model. 
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